Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells

Morphea in adults and children cohort II: Patients with morphea experience delay in diagnosis and large variation in treatment

“…Furthermore, phototherapy was used almost exclusively by dermatologists (albeit infrequently), despite extensive literature supporting its use in morphea. [10][11][12][13][14][15][16] This implies that at least some patients with morphea are receiving suboptimal therapy. To date, treatment recommendations are based on minimal evidence and largely expert opinion.…”

Clinicohistopathological correlations in juvenile localized scleroderma: Studies on a subset of children with hypopigmented juvenile localized scleroderma due to loss of epidermal melanocytes

“…The signals that initiate or reverse the process are not known. One effective therapy for morphea (ultraviolet A light) may reverse the abnormal cytokine microenvironment that perpetuates the imbalance in CD34 1 and FXIIIa 1 cells in dermis in morphea 27 and in scleroderma.…”

A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma

“…So far, low-dose (LD) and medium-dose (MD) UVA1 seems to be as effective as high-dose UVA1, with a possible better risk/benefit ratio. [6][7][8][9][10] The optimal dose and treatment protocol regarding therapeutic efficacy still needs to be evaluated. Nevertheless, limitations in these trials exist including small numbers of patients in open, nonrandomized settings.…”